Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
NCT01419717
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
129
Enrollment
INDUSTRY
Sponsor class
Conditions
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Bone Metastases in Subjects With Advanced Breast Cancer
Interventions
DRUG:
Denosumab
Sponsor
Amgen